Therapix Biosciences Ltd. (NASDAQ: TRPX) rose Monday after the company disclosed topline results of Phase IIa study at Yale University for Tourette Syndrome program.
The Israel-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform THX-110, announced today topline results from its investigator-initiated Phase IIa study at Yale University, suggesting that THX-110 [which is a combination of dronabinol (?-9-tetrahydracannabinol) and palmitoylethanolamide (PEA)] significantly improved symptoms over time in adult Subjects with Tourette syndrome.
So said Therapix Chief Technology Officer Adi Zuloff-Shani "The successful completion of this study is a key milestone in our clinical development plan of our proprietary drug candidate THX-110 for the treatment of Tourette syndrome for which current available treatments are frequently inadequate or unsafe.
"Moreover, these results are of particular interest as the pharmacology of THX-110 appears to be distinct from existing medications for TS and may offer a unique option for treating these patients."
The study was a single-arm, open-label trial, in which each subject both received one daily treatment of the drug via oral administration and was followed-up for a period of 12 weeks. In all, 16 subjects participated in the study and received THX-110 at the Yale University Child Study Center in Connecticut.
Shares in Therapix hiked $1.26, or 24.2% Monday, to $6.46
Related Stories
